Overview

A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion

Status:
Completed

Trial end date:
2016-04-01

Target enrollment:

Participant gender:

Summary

An Open-label, Single arm, Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma with 17p Deletion

Phase:

Phase 2

Details

Lead Sponsor:

Pharmacyclics LLC.

Collaborator:

Janssen Research & Development, LLC